Screener
Merck & Co. MRK D&A
D&A at other companies
Other financials
Where this comes from
Reported directly by Merck & Co. in its filing.
Tagged under the XBRL concept us-gaap:Depreciation.
The source filing: Merck & Co.’s 10-K, filed February 24, 2026.
- Filed
- Feb 24, 2026, 4:15 PM EST
- Fiscal year
- FY2026
- Accession
- 0000310158-26-000063
| Line item | 2025 | 2024 | 2023 |
|---|---|---|---|
| Net income | $18,263 | $17,133 | $377 |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Amortization | 2,793 | 2,395 | 2,044 |
| Depreciation | 3,045 | 2,104 | 1,828 |
| Intangible asset impairment charges | 55 | 39 | 792 |
| Income from investments in equity securities, net | (368) | (14) | (340) |
| Charges for certain research and development asset acquisitions | — | 3,456 | 11,409 |
| Deferred income taxes | (1,671) | (1,249) | (1,899) |
Item 8.Financial Statements and Supplementary Data.
FAQ
- What is Merck & Co.'s D&A?
- Merck & Co. (MRK) reported D&A of $1.49B in Q4 2025.
- How has Merck & Co.'s D&A changed year-over-year?
- Merck & Co.'s D&A increased by 186.0% year-over-year, from $522M to $1.49B.
- What is the long-term trend for Merck & Co.'s D&A?
- Over 4 years (2021 to 2025), Merck & Co.'s D&A has grown at a 17.9% compound annual growth rate (CAGR), from $1.58B to $3.05B.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Merck & Co.'s d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude